Astrazeneca S Evusheld Covid 19 Prevention Drug Given Conditional Approval
Evusheld consists of 100 mg/ml of tixagevimab and cilgavimab, which are administered through two separate intramuscular injections. It is meant as a prevention measure for those aged 12 and above who are especially vulnerable to the virus despite being vaccinated such as those who are immunocompromised, as well as those who cannot take the COVID-19 vaccine. According to clinical trials, the monoclonal antibody combination was successful at reducing the risk of symptomatic COVID-19 by 77%, with no deaths or severe cases....